88 highly profitable Healthcare stocks rated Buy or better (Nov 2026)
88 highly profitable Healthcare stocks rated Buy or better by the Lician Quant rating as of Nov 4, 2026, including NOVO NORDISK A S (NVO), Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals Inc (REGN). Profitability grade A- or better (margins, ROE, ROA and cash generation against sector peers) and a Buy or Strong Buy rating.
Open this screen in the full screener to add filters, sort by any factor and save it.
88 stocks · Strong Buy or Buy · Healthcare · Profitability ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1IRWDIronwood Pharmaceuticals Inc | 4.41Buy | A- | C- | A+ | D+ | A- | $597M | 4.6 | +26.2% | — | — | Nov 5 |
| 2RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
| 3AUPHAurinia Pharmaceuticals Inc | 4.71Strong Buy | B+ | A | A+ | B- | D+ | $2.1B | 6.8 | +21.0% | — | 5.9% | — |
| 4AGENAgenus Inc | 3.85Buy | B | B- | A+ | C+ | F | $291M | 3.2 | +30.5% | — | 18.1% | Nov 5 |
| 5EXELExelixis Inc | 4.69Strong Buy | C+ | B | A+ | A+ | C- | $17.5B | 19.7 | +9.1% | — | 13.4% | — |
| 6ZVRAZevra Therapeutics Inc. | 4.59Strong Buy | A- | A+ | A+ | C | D+ | $582M | 10.0 | +119.4% | — | — | — |
| 7QTTBQ32 Bio Inc | 5.00Strong Buy | A+ | — | A+ | B | A | $206M | 6.1 | — | — | 57.9% | Nov 12 |
| 8MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 9CRMDCorMedix Inc | 4.14Buy | A+ | A+ | A+ | F | D- | $579M | 3.1 | — | — | 22.0% | Nov 11 |
| 10KRYSKrystal Biotech Inc | 3.63Buy | C- | A- | A+ | C+ | F | $9.8B | 40.7 | +22.6% | — | — | — |
| 11LLYEli Lilly and Company | 4.65Strong Buy | — | A | A+ | A+ | F | — | — | +45.5% | 0.56% | — | — |
| 12HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 13CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 14VRTXVertex Pharmaceuticals Inc | 4.74Strong Buy | B- | C+ | A+ | B | A | $135B | 30.7 | +10.2% | — | 1.7% | — |
| 15LQDALiquidia Technologies Inc | 4.15Buy | B | A+ | A+ | C | F | $3.8B | 27.4 | +2,234% | — | 26.1% | — |
| 16UTHRUnited Therapeutics Corporation | 3.99Buy | B+ | C | A+ | B | F | $25.6B | 19.5 | +2.5% | — | — | Nov 4 |
| 17NVONOVO NORDISK A S | 4.24Buy | A- | C | A+ | D+ | — | $179B | 11.5 | +11.0% | — | — | Nov 4 |
| 18MEDPMedpace Holdings Inc | 4.78Strong Buy | B- | B+ | A+ | A- | B- | $17.3B | 35.2 | +24.7% | — | 7.2% | — |
| 19INVAInnoviva Inc | 4.89Strong Buy | A+ | B+ | A+ | C- | A- | $1.5B | 4.3 | +18.8% | — | 10.5% | Nov 4 |
| 20TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | 4.36Buy | — | D- | A+ | A | — | — | — | -90.6% | — | — | — |
| 21REGNRegeneron Pharmaceuticals Inc | 4.95Strong Buy | B+ | C+ | A+ | A | A | $103B | 21.5 | +18.6% | — | 2.1% | — |
| 22ACADACADIA Pharmaceuticals Inc | 4.75Strong Buy | A | A- | A+ | D | B+ | $3.3B | 8.7 | +11.8% | — | 7.9% | Nov 4 |
| 23DOCSDoximity Inc | 4.24Buy | B | C+ | A+ | B | C- | $5.6B | 33.3 | +11.2% | — | 7.1% | Nov 5 |
| 24IRMDIradimed Co | 4.05Buy | C- | B- | A+ | D | A | $1.0B | 42.3 | +11.0% | 0.79% | 8.1% | — |
| 25NBIXNeurocrine Biosciences Inc | 4.87Strong Buy | B+ | A | A+ | B- | B | $14.7B | 21.0 | +38.0% | — | 6.6% | — |
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Most profitable in other sectors
About this screen
- Which are the top highly profitable Healthcare stocks rated Buy or better?
- As of Nov 4, 2026, the highest ranked are Ironwood Pharmaceuticals Inc (IRWD, rating 4.41); Rigel Pharmaceuticals Inc (RIGL, rating 4.82); Aurinia Pharmaceuticals Inc (AUPH, rating 4.71); Agenus Inc (AGEN, rating 3.85); Exelixis Inc (EXEL, rating 4.69). 88 stocks pass the screen in total.
- What does this screen look for?
- Profitability grade A- or better (margins, ROE, ROA and cash generation against sector peers) and a Buy or Strong Buy rating.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.